Skip to main content
Top
Published in: Journal of Urban Health 2/2010

01-03-2010

Prevalence and Incidence of HCV Infection among Vietnam Heroin Users with Recent Onset of Injection

Authors: Michael C. Clatts, Vivian Colón-López, Le M. Giang, Lloyd A. Goldsamt

Published in: Journal of Urban Health | Issue 2/2010

Login to get access

Abstract

HCV infection continues to spread at an alarming rate among IDU populations. The available evidence suggests that HCV is acquired relatively quickly following onset of injection. However, there are few prospective studies of HCV acquisition, particularly among IDU populations in resource-poor settings. A sample of young male heroin injectors with recent onset of injection (<4 years) was recruited in Hanoi, Vietnam for a prospective assessment of the early course of injection (n = 179). Both behavioral and biological assessments (including detailed retrospective assessment of injection initiation) were conducted at baseline and repeated at 6-month intervals for a period of 16 months. Variables associated with HCV infection (p value < 0.05) in bivariate analyses were considered for inclusion in logistic regression models to identify risk factors independently associated with HCV infection. HCV incidence was calculated by using the incidence density approach and was expressed in terms of person-years of observation. The baseline of prevalence of HCV was 46%. HCV significantly increased in relation to time since first injection, from 30% in subjects with ≤10 months of injection risk to 70% in subjects with ≥30 months injection risk (p value = 0.0005). In multivariate logistic regression analysis, increasing age, incarceration in a drug detention facility (OR = 2.54; 95%CI 1.05, 6.15), and time since first injection remained significantly associated with HCV infection. Use of injection as primary mode of administration (OR = 2.56; 95%CI 0.98, 6.69) achieved marginal significance. After 16 months of follow-up, the incidence rate of HCV was 23.35 per 100 person-years and the mean time between first injection and first positive HCV test was 1.2 years. HCV is acquired much more rapidly among new injector populations than previously recognized, demonstrating the need for early behavioral intervention among new heroin-user populations. Particularly critical are interventions that target new heroin user populations, including interventions that improve understanding of viral transmission dynamics, that promote alternative strategies for drug sharing, and that delay initiation of injection.
Literature
1.
go back to reference Day C, Dolan K. Correlates of hepatitis C testing among heroin injectors in Sydney. Health Promot J Austr. 2006; 17(1): 70–72.PubMed Day C, Dolan K. Correlates of hepatitis C testing among heroin injectors in Sydney. Health Promot J Austr. 2006; 17(1): 70–72.PubMed
2.
go back to reference Garfield J, Drucker E. Fatal overdose trends in major US cities: 1990–1997. Addictions Research and Theory. 2001; 9(5): 425–436.CrossRef Garfield J, Drucker E. Fatal overdose trends in major US cities: 1990–1997. Addictions Research and Theory. 2001; 9(5): 425–436.CrossRef
3.
go back to reference Wood E, Kerr T, Stoltz J, et al. Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facility. Public Health. 2005; 119(12): 1111–1115.CrossRefPubMed Wood E, Kerr T, Stoltz J, et al. Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facility. Public Health. 2005; 119(12): 1111–1115.CrossRefPubMed
5.
go back to reference Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D. Correlates of HIV infection among young adult short-term injection drug users. AIDS. 2000; 14(6): 717–726.CrossRefPubMed Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D. Correlates of HIV infection among young adult short-term injection drug users. AIDS. 2000; 14(6): 717–726.CrossRefPubMed
6.
go back to reference Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996; 86(5): 655–661.CrossRefPubMedPubMedCentral Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996; 86(5): 655–661.CrossRefPubMedPubMedCentral
7.
go back to reference Hagan H, Thiede H, Des Jarlais DC. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology. 2004; 15(5): 543–549.CrossRefPubMed Hagan H, Thiede H, Des Jarlais DC. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology. 2004; 15(5): 543–549.CrossRefPubMed
8.
go back to reference Hagan H, Des Jarlais DC, Stern R, et al. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy. 2007; 18(5): 341–351.CrossRefPubMed Hagan H, Des Jarlais DC, Stern R, et al. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy. 2007; 18(5): 341–351.CrossRefPubMed
9.
go back to reference Roy E, Haley N, Leclerc P, Cédras L, Boivin JF. Drug injection among street youth: the first time. Addiction. 2002; 97(8): 1003–1009.CrossRefPubMed Roy E, Haley N, Leclerc P, Cédras L, Boivin JF. Drug injection among street youth: the first time. Addiction. 2002; 97(8): 1003–1009.CrossRefPubMed
10.
go back to reference van Ameijden EJ, van den Hoek JA, Hartgers C, Coutinho RA. Risk factors for the transition from noninjection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users. Am J Epidemiol. 1994; 139(12): 1153–1163.CrossRefPubMed van Ameijden EJ, van den Hoek JA, Hartgers C, Coutinho RA. Risk factors for the transition from noninjection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users. Am J Epidemiol. 1994; 139(12): 1153–1163.CrossRefPubMed
11.
go back to reference Clatts MC, Goldsamt LA, Yi H. Drug and sexual risk in four men who have sex with men populations: evidence for a sustained HIV epidemic in New York City. J Urban Health. 2005; 82(1 Suppl 1): i9–i17.CrossRefPubMedPubMedCentral Clatts MC, Goldsamt LA, Yi H. Drug and sexual risk in four men who have sex with men populations: evidence for a sustained HIV epidemic in New York City. J Urban Health. 2005; 82(1 Suppl 1): i9–i17.CrossRefPubMedPubMedCentral
12.
go back to reference Allison PD. Logistic Regression Using the SAS System: theory and Application. Cary, NC; 1999. Allison PD. Logistic Regression Using the SAS System: theory and Application. Cary, NC; 1999.
13.
go back to reference Szklo M, Nieto FJ. Epidemiology: beyond the Basics. 2nd ed. Gaithersburg, Maryland; 2004. Szklo M, Nieto FJ. Epidemiology: beyond the Basics. 2nd ed. Gaithersburg, Maryland; 2004.
14.
go back to reference Clatts MC, Giang LM, Goldsamt LA, Yi H. Novel heroin injection practices: implications for transmission of HIV and other bloodborne pathogens. Am J Prev Med. 2007; 32(6 Suppl): S226–S233.CrossRefPubMedPubMedCentral Clatts MC, Giang LM, Goldsamt LA, Yi H. Novel heroin injection practices: implications for transmission of HIV and other bloodborne pathogens. Am J Prev Med. 2007; 32(6 Suppl): S226–S233.CrossRefPubMedPubMedCentral
15.
go back to reference Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001; 34(1): 180–187.CrossRefPubMed Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001; 34(1): 180–187.CrossRefPubMed
16.
go back to reference Miller CL, Johnston C, Spittal PM, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology. 2002; 36(3): 737–742.CrossRefPubMed Miller CL, Johnston C, Spittal PM, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology. 2002; 36(3): 737–742.CrossRefPubMed
17.
go back to reference Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997–1999. J Infect Dis. 2000; 182(6): 1588–1594.CrossRefPubMed Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997–1999. J Infect Dis. 2000; 182(6): 1588–1594.CrossRefPubMed
18.
go back to reference Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 18(Suppl 1): S11–S19.CrossRefPubMed Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 18(Suppl 1): S11–S19.CrossRefPubMed
19.
go back to reference Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. HIV and hepatitis C coinfection within the CAESAR study. HIV Med. 2004; 5(3): 174–179.CrossRefPubMed Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. HIV and hepatitis C coinfection within the CAESAR study. HIV Med. 2004; 5(3): 174–179.CrossRefPubMed
20.
go back to reference Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003; 33(3): 365–372.CrossRefPubMed Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003; 33(3): 365–372.CrossRefPubMed
21.
go back to reference Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000; 356(9244): 1800–1805.CrossRefPubMed Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000; 356(9244): 1800–1805.CrossRefPubMed
22.
go back to reference Fainboim H, González J, Fassio E, et al. Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepat. 1999; 6(1): 53–57.CrossRefPubMed Fainboim H, González J, Fassio E, et al. Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepat. 1999; 6(1): 53–57.CrossRefPubMed
23.
go back to reference Solomon SS, Srikrishnan AK, Mehta SH, et al. High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr. 2008; 49(3): 327–332.CrossRefPubMedPubMedCentral Solomon SS, Srikrishnan AK, Mehta SH, et al. High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr. 2008; 49(3): 327–332.CrossRefPubMedPubMedCentral
25.
go back to reference Maher L, Jalaludin B, Chant KG, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction. 2006; 101(10): 1499–1508.CrossRefPubMed Maher L, Jalaludin B, Chant KG, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction. 2006; 101(10): 1499–1508.CrossRefPubMed
26.
go back to reference Roy E, Boudreau JF, Boivin JF. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend. 2009; 102(1–3): 158–161.CrossRefPubMed Roy E, Boudreau JF, Boivin JF. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend. 2009; 102(1–3): 158–161.CrossRefPubMed
27.
go back to reference Kapadia F, Latka MH, Hagan H, et al. Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study to Reduce Intravenous Exposures (STRIVE). J Urban Health. 2007; 84(1): 99–115.CrossRefPubMedPubMedCentral Kapadia F, Latka MH, Hagan H, et al. Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study to Reduce Intravenous Exposures (STRIVE). J Urban Health. 2007; 84(1): 99–115.CrossRefPubMedPubMedCentral
28.
go back to reference Clatts MC, Heimer R, Abdala N, et al. HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. J Acquir Immune Defic Syndr. 1999; 22(2): 194–199.CrossRefPubMed Clatts MC, Heimer R, Abdala N, et al. HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. J Acquir Immune Defic Syndr. 1999; 22(2): 194–199.CrossRefPubMed
Metadata
Title
Prevalence and Incidence of HCV Infection among Vietnam Heroin Users with Recent Onset of Injection
Authors
Michael C. Clatts
Vivian Colón-López
Le M. Giang
Lloyd A. Goldsamt
Publication date
01-03-2010
Publisher
Springer US
Published in
Journal of Urban Health / Issue 2/2010
Print ISSN: 1099-3460
Electronic ISSN: 1468-2869
DOI
https://doi.org/10.1007/s11524-009-9417-9

Other articles of this Issue 2/2010

Journal of Urban Health 2/2010 Go to the issue